KR20020038759A - 벤즈이미다졸계 화합물 안정화 방법 - Google Patents
벤즈이미다졸계 화합물 안정화 방법 Download PDFInfo
- Publication number
- KR20020038759A KR20020038759A KR1020027003596A KR20027003596A KR20020038759A KR 20020038759 A KR20020038759 A KR 20020038759A KR 1020027003596 A KR1020027003596 A KR 1020027003596A KR 20027003596 A KR20027003596 A KR 20027003596A KR 20020038759 A KR20020038759 A KR 20020038759A
- Authority
- KR
- South Korea
- Prior art keywords
- physiologically acceptable
- crospovidone
- acceptable salt
- benzimidazole
- benzimidazole compound
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 32
- 230000000087 stabilizing effect Effects 0.000 title claims abstract description 18
- 125000003785 benzimidazolyl group Chemical class N1=C(NC2=C1C=CC=C2)* 0.000 title 1
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims abstract description 75
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims abstract description 56
- 229960000913 crospovidone Drugs 0.000 claims abstract description 56
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims abstract description 56
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims abstract description 56
- -1 benzimidazole compound Chemical class 0.000 claims abstract description 48
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims abstract description 42
- 150000003839 salts Chemical class 0.000 claims abstract description 36
- 239000011248 coating agent Substances 0.000 claims description 20
- 238000000576 coating method Methods 0.000 claims description 20
- 150000001875 compounds Chemical class 0.000 claims description 17
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 14
- 239000011734 sodium Substances 0.000 claims description 14
- 229910052708 sodium Inorganic materials 0.000 claims description 14
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 claims description 11
- 239000002702 enteric coating Substances 0.000 claims description 10
- 238000009505 enteric coating Methods 0.000 claims description 10
- 238000002156 mixing Methods 0.000 claims description 9
- 229910052739 hydrogen Inorganic materials 0.000 claims description 6
- 239000001257 hydrogen Substances 0.000 claims description 6
- 150000002431 hydrogen Chemical class 0.000 claims description 4
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- IQPSEEYGBUAQFF-UHFFFAOYSA-N Pantoprazole Chemical compound COC1=CC=NC(CS(=O)C=2NC3=CC=C(OC(F)F)C=C3N=2)=C1OC IQPSEEYGBUAQFF-UHFFFAOYSA-N 0.000 claims description 2
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 claims description 2
- 229960003174 lansoprazole Drugs 0.000 claims description 2
- MJIHNNLFOKEZEW-UHFFFAOYSA-N lansoprazole Chemical compound CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1 MJIHNNLFOKEZEW-UHFFFAOYSA-N 0.000 claims description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 229960000381 omeprazole Drugs 0.000 claims description 2
- 229960005019 pantoprazole Drugs 0.000 claims description 2
- 229960004157 rabeprazole Drugs 0.000 claims description 2
- YREYEVIYCVEVJK-UHFFFAOYSA-N rabeprazole Chemical compound COCCCOC1=CC=NC(CS(=O)C=2NC3=CC=CC=C3N=2)=C1C YREYEVIYCVEVJK-UHFFFAOYSA-N 0.000 claims description 2
- 230000006641 stabilisation Effects 0.000 claims description 2
- 238000011105 stabilization Methods 0.000 claims description 2
- 125000003652 trifluoroethoxy group Chemical group FC(CO*)(F)F 0.000 claims description 2
- 239000000203 mixture Substances 0.000 abstract description 29
- 238000002360 preparation method Methods 0.000 abstract description 6
- 239000007787 solid Substances 0.000 abstract description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 24
- 238000009472 formulation Methods 0.000 description 20
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 13
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 13
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 13
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 13
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 11
- 239000012535 impurity Substances 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 7
- 229930195725 Mannitol Natural products 0.000 description 7
- 238000004128 high performance liquid chromatography Methods 0.000 description 7
- 239000000594 mannitol Substances 0.000 description 7
- 235000010355 mannitol Nutrition 0.000 description 7
- 150000001556 benzimidazoles Chemical class 0.000 description 6
- 235000019359 magnesium stearate Nutrition 0.000 description 6
- 239000001856 Ethyl cellulose Substances 0.000 description 5
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 229920001249 ethyl cellulose Polymers 0.000 description 5
- 235000019325 ethyl cellulose Nutrition 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- 229910000029 sodium carbonate Inorganic materials 0.000 description 5
- 238000003860 storage Methods 0.000 description 5
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 4
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 3
- 238000004040 coloring Methods 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 238000000354 decomposition reaction Methods 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 238000004321 preservation Methods 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- JEIPFZHSYJVQDO-UHFFFAOYSA-N ferric oxide Chemical compound O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 238000005550 wet granulation Methods 0.000 description 2
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
- ZGDLVKWIZHHWIR-UHFFFAOYSA-N 4-[5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl]morpholine Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC=C(N2CCOCC2)N=C1 ZGDLVKWIZHHWIR-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 102100021904 Potassium-transporting ATPase alpha chain 1 Human genes 0.000 description 1
- 108010083204 Proton Pumps Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 239000011247 coating layer Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 230000027119 gastric acid secretion Effects 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N iron oxide Inorganic materials [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 1
- 229940117841 methacrylic acid copolymer Drugs 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 239000008183 oral pharmaceutical preparation Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 229960001778 rabeprazole sodium Drugs 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
Description
처방 | 대조예1 | 실시예1 | 실시예2 | 실시예3 |
라베프라졸나트륨만니톨크로스포비돈하이드록시프로필 셀룰로오스스테아르산 마그네슘 | 20.0125.4-3.01.6 | 20.0105.420.03.01.6 | 20.085.440.03.01.6 | 20.065.460.03.01.6 |
(소 계) | 150.0 | 150.0 | 150.0 | 150.0 |
제제 물성 | ||||
색차(△E) | 40.93 | 23.75 | 16.18 | 14.38 |
처방 | 실시예2 | 실시예4 | 실시예5 | 대조예2 |
라베프라졸나트륨만니톨크로스포비돈수산화나트륨무수 탄산나트륨하이드록시프로필 셀룰로오스스테아르산 마그네슘 | 20.085.440.0--3.01.6 | 20.084.840.00.6-3.01.6 | 20.084.440.01.0-3.01.6 | 20.075.440.0-10.03.01.6 |
(소 계) | 150.0 | 150.0 | 150.0 | 150.0 |
제제 물성 | ||||
색차(△E) | 16.18 | 17.45 | 17.88 | 17.27 |
붕괴 시간(분)냉소 보존품40℃상대습도75% 보존품(개방하) | 5.8∼6.28.1∼10.1 | 3.6∼4.14.0∼5.1 | 3.7∼4.05.5∼6.1 | 7.3∼8.122.8∼24.0 |
HPLC 불순물량(%)40℃상대습도75% 보존품(개방하) | 2.99 | 2.38 | 2.31 | 1.96 |
Claims (8)
- 하기 구조식(식 1)으로 나타내어지는 벤즈이미다졸계 화합물 또는 그것의 생리학적으로 허용되는 염에 크로스포비돈을 배합하는 것을 특징으로 하는 벤즈이미다졸계 화합물 또는 그것의 생리학적으로 허용되는 염의 안정화 방법:[식 1]식 1에서 Het1은이고, Het2는이며,R1및 R2는 동일하거나 상이하고, 수소, 메톡시 및 디플루오로메톡시로부터 선택되고, R3은 수소 및 나트륨으로부터 선택되고, R4, R5및 R6는 동일하거나 상이하고, 수소, 메틸, 메톡시, 메톡시프로폭시 및 트리플루오로에톡시로부터 선택됨.
- 상기 식 1로 나타내어지는 벤즈이미다졸계 화합물 또는 그것의 생리학적으로 허용되는 염에 1) 크로스포비돈 및 2) 수산화나트륨 및/또는 수산화칼륨을 배합하는 것을 특징으로 하는 벤즈이미다졸계 화합물 또는 그것의 생리학적으로 허용되는 염의 안정화 방법.
- 상기 식 1로 나타내어지는 벤즈이미다졸계 화합물 또는 그것의 생리학적으로 허용되는 염에 크로스포비돈 또는 1) 크로스포비돈 및 2) 수산화나트륨 및/또는 수산화칼륨을 배합하여 이루어지는 핵에 장용성(腸溶性) 피막을 피복하는 것을 특징으로 하는 벤즈이미다졸계 화합물 또는 그것의 생리학적으로 허용되는 염의 안정화 방법.
- 상기 식 1로 나타내어지는 벤즈이미다졸계 화합물 또는 그것의 생리학적으로 허용되는 염에 크로스포비돈 또는 1) 크로스포비돈 및 2) 수산화나트륨 및/또는 수산화칼륨을 배합하여 이루어지는 핵에 중간 피막을 피복하고, 또한 장용성 피막을 피복하는 것을 특징으로 하는 벤즈이미다졸계 화합물 또는 그것의 생리학적으로 허용되는 염의 안정화 방법.
- 제1항 내지 제4항 중 어느 한 항에 있어서,벤즈이미다졸계 화합물 또는 그것의 생리학적으로 허용되는 염과 크로스포비돈과의 배합 비율이 벤즈이미다졸계 화합물 또는 그것의 생리학적으로 허용되는 염 1중량부에 대해 0.5∼5중량부인 안정화 방법.
- 제1항 내지 제5항 중 어느 한 항에 있어서,벤즈이미다졸계 화합물 또는 그것의 생리학적으로 허용되는 염이 라베프라졸, 오메프라졸, 판토프라졸, 란소프라졸 또는 그것들의 생리학적으로 허용되는 염인 안정화 방법.
- 제1항 내지 제6항 중 어느 한 항에 있어서,안정화 방법이 벤즈이미다졸계 화합물 또는 그것의 생리학적으로 허용되는 염의 착색 변화를 방지하는 방법인 안정화 방법.
- 제1항에 정의된 벤즈이미다졸계 화합물 또는 그것의 생리학적으로 허용되는 염에 크로스포비돈을 배합하는 것을 특징으로 하는 벤즈이미다졸계 화합물 또는 그것의 생리학적으로 허용되는 염의 착색 변화를 방지하는 방법.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JPJP-P-1999-00298063 | 1999-10-20 | ||
JP29806399 | 1999-10-20 | ||
PCT/JP2000/007285 WO2001028559A1 (fr) | 1999-10-20 | 2000-10-19 | Procede de stabilisation de composes benzimidazoles |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20020038759A true KR20020038759A (ko) | 2002-05-23 |
Family
ID=17854666
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020027003596A KR20020038759A (ko) | 1999-10-20 | 2000-10-19 | 벤즈이미다졸계 화합물 안정화 방법 |
Country Status (19)
Country | Link |
---|---|
US (1) | US7220762B1 (ko) |
EP (1) | EP1222922B1 (ko) |
JP (1) | JP4081273B2 (ko) |
KR (1) | KR20020038759A (ko) |
CN (1) | CN1197574C (ko) |
AT (1) | ATE369857T1 (ko) |
AU (1) | AU782538B2 (ko) |
CA (1) | CA2387746C (ko) |
CY (1) | CY1107506T1 (ko) |
DE (1) | DE60036014T2 (ko) |
DK (1) | DK1222922T3 (ko) |
ES (1) | ES2288876T3 (ko) |
HU (1) | HU229213B1 (ko) |
MX (1) | MXPA02003762A (ko) |
NO (1) | NO329940B1 (ko) |
PT (1) | PT1222922E (ko) |
RU (1) | RU2259828C2 (ko) |
TW (1) | TWI268779B (ko) |
WO (1) | WO2001028559A1 (ko) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100627614B1 (ko) * | 1998-04-20 | 2006-09-25 | 에자이 가부시키가이샤 | 안정화된 벤즈이미다졸계 화합물 함유 조성물로 이루어지는 의약제제 |
AR036354A1 (es) * | 2001-08-31 | 2004-09-01 | Takeda Chemical Industries Ltd | Preparacion solida |
BR0214372A (pt) * | 2001-11-21 | 2004-10-26 | Eisai Co Ltd | Composição de um preparado contendo um composto ácido-instavel fisiologicamente ativo e processo para a produção da mesma |
US20050163846A1 (en) * | 2001-11-21 | 2005-07-28 | Eisai Co., Ltd. | Preparation composition containing acid-unstable physiologically active compound, and process for producing same |
WO2004003908A1 (en) | 2002-06-28 | 2004-01-08 | Lg Electronics Inc. | Recording medium having data structure for managing recording and reproduction of multiple path data recorded thereon and recording and reproducing methods and apparatus |
US7720356B2 (en) | 2002-11-12 | 2010-05-18 | Lg Electronics Inc | Recording medium having data structure for managing reproduction of multiple reproduction path video data recorded thereon and recording and reproducing methods and apparatuses |
US7664372B2 (en) | 2002-11-20 | 2010-02-16 | Lg Electronics Inc. | Recording medium having data structure for managing reproduction of multiple component data recorded thereon and recording and reproducing methods and apparatuses |
TW200503783A (en) * | 2003-04-11 | 2005-02-01 | Altana Pharma Ag | Oral pharmaceutical preparation for proton pump antagonists |
US8993599B2 (en) | 2003-07-18 | 2015-03-31 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
TWI372066B (en) * | 2003-10-01 | 2012-09-11 | Wyeth Corp | Pantoprazole multiparticulate formulations |
CA2557791C (en) * | 2004-03-26 | 2011-03-08 | Eisai R&D Management Co., Ltd. | Controlled-release pharmaceutical composition and method for producing the same |
US8815916B2 (en) | 2004-05-25 | 2014-08-26 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
US8906940B2 (en) | 2004-05-25 | 2014-12-09 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
US20090148519A1 (en) * | 2005-09-29 | 2009-06-11 | Yasuhiro Zaima | Pulsed-release preparation having improved disintegration properties in vivo |
US20100105738A1 (en) * | 2006-10-06 | 2010-04-29 | Mitsuru Mizuno | Extended release formulations of a proton pump inhibitor |
CN100411613C (zh) * | 2006-12-08 | 2008-08-20 | 中国药科大学 | 一种奥美拉唑速释固体制剂及其制备方法 |
WO2008129517A2 (en) * | 2007-04-23 | 2008-10-30 | Ranbaxy Laboratories Limited | A stabilized delayed release pharmaceutical composition of rabeprazole |
JP5399749B2 (ja) * | 2008-03-27 | 2014-01-29 | 沢井製薬株式会社 | プロトンポンプ阻害剤を含有する被覆微粒子 |
WO2010117756A2 (en) * | 2009-03-31 | 2010-10-14 | Dr. Reddy's Laboratories Ltd | Substituted benzimidazole pharmaceutical formulations |
US20150209432A1 (en) | 2012-07-26 | 2015-07-30 | Lupin Limited | Pharmaceutical compositions of proton pump inhibitor |
RU2554735C1 (ru) * | 2014-08-20 | 2015-06-27 | Открытое Акционерное Общество "Татхимфармпрепараты" | Фармацевтическая композиция, содержащая рабепразол натрия, и способ ее получения |
KR102227486B1 (ko) * | 2017-06-30 | 2021-03-12 | 롯데정밀화학 주식회사 | 프로톤 펌프 저해제를 포함하는 경구용 고형제제 조성물, 이를 포함하는 경구용 고형제제 및 그 제조방법 |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB189698A (en) | 1921-12-29 | 1922-12-07 | Miniere & Ind Franco Bresilien | Method for the treatment of monazite and other phosphate ores |
US4471638A (en) * | 1982-03-26 | 1984-09-18 | Steelcase Inc. | Front removable lock |
JPS62277322A (ja) | 1986-02-13 | 1987-12-02 | Takeda Chem Ind Ltd | 安定化された腸溶性抗潰瘍固形組成物 |
CA1327010C (en) | 1986-02-13 | 1994-02-15 | Tadashi Makino | Stabilized solid pharmaceutical composition containing antiulcer benzimidazole compound and its production |
ZA871177B (en) | 1986-02-21 | 1988-10-26 | Nihon Nohyaku Co Ltd | 1,3-diketone derivatives and their use |
GB2189698A (en) | 1986-04-30 | 1987-11-04 | Haessle Ab | Coated omeprazole tablets |
GB2189699A (en) | 1986-04-30 | 1987-11-04 | Haessle Ab | Coated acid-labile medicaments |
AU619444B2 (en) | 1986-06-02 | 1992-01-30 | Nippon Chemiphar Co. Ltd. | 2-(2-aminobenzylsulfinyl)- benzimidazole derivatives |
SE8804629D0 (sv) | 1988-12-22 | 1988-12-22 | Ab Haessle | New therapeutically active compounds |
YU48263B (sh) | 1991-06-17 | 1997-09-30 | Byk Gulden Lomberg Chemische Fabrik Gmbh. | Postupak za dobijanje farmaceutskog preparata na bazi pantoprazola |
JPH0656665A (ja) | 1992-08-03 | 1994-03-01 | Nippon Chemiphar Co Ltd | イミダゾール誘導体を含有する胃溶性抗潰瘍剤 |
SE9301830D0 (sv) * | 1993-05-28 | 1993-05-28 | Ab Astra | New compounds |
SE9302395D0 (sv) | 1993-07-09 | 1993-07-09 | Ab Astra | New pharmaceutical formulation |
ES2316333T3 (es) | 1994-07-08 | 2009-04-16 | Astrazeneca Ab | Forma de dosificacion en tabletas constituida por unidades multiples. |
ES2094694B1 (es) | 1995-02-01 | 1997-12-16 | Esteve Quimica Sa | Nueva formulacion farmaceuticamente estable de un compuesto de bencimidazol y su proceso de obtencion. |
US5708017A (en) | 1995-04-04 | 1998-01-13 | Merck & Co., Inc. | Stable, ready-to-use pharmaceutical paste composition containing proton pump inhibitors |
DE69628444T2 (de) * | 1995-09-21 | 2004-05-06 | Pharma Pass Ii Llc, Irvine | Säurelabile omeprazol enthaltende pharmazeutische zusammensetzung und verfahren zu dessen herstellung |
BE1009764A3 (nl) | 1995-11-06 | 1997-08-05 | Dsm Nv | Werkwijze voor de bereiding van een alpha-alkylkaneelaldehyde. |
US6645988B2 (en) | 1996-01-04 | 2003-11-11 | Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and method of using same |
SE9600071D0 (sv) | 1996-01-08 | 1996-01-08 | Astra Ab | New oral formulation of two active ingredients I |
JPH09216817A (ja) | 1996-02-08 | 1997-08-19 | Amano Pharmaceut Co Ltd | 防湿性且つ易水崩壊性コーティング製剤 |
DE69713948D1 (de) | 1996-04-23 | 2002-08-22 | Janssen Pharmaceutica Nv | Rasch-freisetzende pH-unabhängige feste Dosisformen enthaltend Cisaprid |
WO1997049703A2 (en) | 1996-06-25 | 1997-12-31 | Takeda Chemical Industries, Ltd. | Oxazolone derivatives and their use as anti-helicobacter pylori agents |
GB9710800D0 (en) * | 1997-05-23 | 1997-07-23 | Cipla Limited | Pharmaceutical composition and method of preparing it |
TW580397B (en) * | 1997-05-27 | 2004-03-21 | Takeda Chemical Industries Ltd | Solid preparation |
SE9702000D0 (sv) | 1997-05-28 | 1997-05-28 | Astra Ab | New pharmaceutical formulation |
US6296876B1 (en) | 1997-10-06 | 2001-10-02 | Isa Odidi | Pharmaceutical formulations for acid labile substances |
US20050244497A1 (en) | 1997-11-05 | 2005-11-03 | Wockhardt Limited | Delayed delivery system for acid-sensitive drugs |
KR100627614B1 (ko) | 1998-04-20 | 2006-09-25 | 에자이 가부시키가이샤 | 안정화된 벤즈이미다졸계 화합물 함유 조성물로 이루어지는 의약제제 |
ZA9810765B (en) | 1998-05-28 | 1999-08-06 | Ranbaxy Lab Ltd | Stable oral pharmaceutical composition containing a substituted pyridylsulfinyl benzimidazole. |
US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
US20040028737A1 (en) | 2002-08-12 | 2004-02-12 | Kopran Research Laboratories Limited | Enteric coated stable oral pharmaceutical composition of acid unstable drug and process for preparing the same |
-
2000
- 2000-10-19 JP JP2001531389A patent/JP4081273B2/ja not_active Expired - Fee Related
- 2000-10-19 CN CNB008145970A patent/CN1197574C/zh not_active Expired - Fee Related
- 2000-10-19 ES ES00969905T patent/ES2288876T3/es not_active Expired - Lifetime
- 2000-10-19 DK DK00969905T patent/DK1222922T3/da active
- 2000-10-19 PT PT00969905T patent/PT1222922E/pt unknown
- 2000-10-19 HU HU0203333A patent/HU229213B1/hu not_active IP Right Cessation
- 2000-10-19 AU AU79502/00A patent/AU782538B2/en not_active Ceased
- 2000-10-19 WO PCT/JP2000/007285 patent/WO2001028559A1/ja active IP Right Grant
- 2000-10-19 RU RU2002113104/04A patent/RU2259828C2/ru not_active IP Right Cessation
- 2000-10-19 KR KR1020027003596A patent/KR20020038759A/ko active Search and Examination
- 2000-10-19 CA CA2387746A patent/CA2387746C/en not_active Expired - Fee Related
- 2000-10-19 EP EP00969905A patent/EP1222922B1/en not_active Expired - Lifetime
- 2000-10-19 DE DE60036014T patent/DE60036014T2/de not_active Expired - Lifetime
- 2000-10-19 TW TW089121923A patent/TWI268779B/zh not_active IP Right Cessation
- 2000-10-19 AT AT00969905T patent/ATE369857T1/de active
- 2000-10-19 MX MXPA02003762A patent/MXPA02003762A/es active IP Right Grant
- 2000-10-19 US US10/110,679 patent/US7220762B1/en not_active Expired - Lifetime
-
2002
- 2002-04-19 NO NO20021875A patent/NO329940B1/no not_active IP Right Cessation
-
2007
- 2007-10-24 CY CY20071101368T patent/CY1107506T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
EP1222922A1 (en) | 2002-07-17 |
CN1382049A (zh) | 2002-11-27 |
HUP0203333A3 (en) | 2004-01-28 |
DK1222922T3 (da) | 2007-12-03 |
ES2288876T3 (es) | 2008-02-01 |
AU7950200A (en) | 2001-04-30 |
CN1197574C (zh) | 2005-04-20 |
JP4081273B2 (ja) | 2008-04-23 |
HU229213B1 (en) | 2013-09-30 |
ATE369857T1 (de) | 2007-09-15 |
WO2001028559A1 (fr) | 2001-04-26 |
NO20021875L (no) | 2002-06-04 |
EP1222922B1 (en) | 2007-08-15 |
AU782538B2 (en) | 2005-08-04 |
PT1222922E (pt) | 2007-09-12 |
MXPA02003762A (es) | 2002-09-30 |
NO329940B1 (no) | 2011-01-24 |
CA2387746A1 (en) | 2001-04-26 |
DE60036014T2 (de) | 2008-04-30 |
TWI268779B (en) | 2006-12-21 |
US7220762B1 (en) | 2007-05-22 |
EP1222922A4 (en) | 2006-04-12 |
DE60036014D1 (de) | 2007-09-27 |
CY1107506T1 (el) | 2013-03-13 |
NO20021875D0 (no) | 2002-04-19 |
CA2387746C (en) | 2010-06-29 |
RU2259828C2 (ru) | 2005-09-10 |
HUP0203333A2 (hu) | 2003-02-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR20020038759A (ko) | 벤즈이미다졸계 화합물 안정화 방법 | |
KR100627614B1 (ko) | 안정화된 벤즈이미다졸계 화합물 함유 조성물로 이루어지는 의약제제 | |
DK2468281T3 (en) | Quinolinderivatholdig pharmaceutical composition | |
EP3090730B1 (en) | Tablets comprising eltrombopag olamine | |
KR101104349B1 (ko) | 에소메프라졸 함유 약학 조성물 | |
SE523481C2 (sv) | Läkemedelskomposition innehållande en HMG-CoA-reduktashämmare och ett organiskt salt med flervärd katjon | |
JP4127740B2 (ja) | 安定化したベンズイミダゾール系化合物含有組成物 | |
EP1981485B1 (en) | Solid pharmaceutical composition comprising irbesartan hydrochloride | |
JP2002154948A (ja) | 崩壊性に優れた錠剤 | |
JPH05255088A (ja) | 抗潰瘍剤含有製剤 | |
EP1736156A1 (en) | STABILIZED 4-AMINO-5-CHLORO-N-¬(1R,3r,5S)-8-METHYL-8- AZABICYCLO¬3.2.1|OCT-3-YL|-2-¬1-METHYLBUT-2-YNYLOXY|-BENZAMIDE CONTAINING COMPOSITION | |
JPH0733659A (ja) | 抗潰瘍剤含有製剤 | |
JP2001270827A (ja) | ベンズイミダゾール系化合物含有錠剤 | |
JPH10273440A (ja) | ピリダジノン化合物類の経口製剤 | |
JPH0222225A (ja) | 胃酸分泌抑制剤含有固型製剤 | |
EP2032126B1 (en) | Rabeprazole formulation | |
JPH05194224A (ja) | 安定化された抗潰瘍剤含有製剤 | |
US20040208932A1 (en) | Stabilized paroxetine hydrochloride formulation | |
KR100761040B1 (ko) | 산 불안정성 벤즈이미다졸계 화합물을 포함하는 약학조성물 | |
KR100761041B1 (ko) | 산 불안정성 벤즈이미다졸계 화합물을 포함하는 약학조성물 | |
WO2019194772A2 (en) | Modified release formulations of fesoterodine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
E601 | Decision to refuse application | ||
J201 | Request for trial against refusal decision | ||
AMND | Amendment | ||
B601 | Maintenance of original decision after re-examination before a trial | ||
N231 | Notification of change of applicant | ||
J301 | Trial decision |
Free format text: TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20061228 Effective date: 20070921 Free format text: TRIAL NUMBER: 2006101011262; TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20061228 Effective date: 20070921 |
|
J2X1 | Appeal (before the patent court) |
Free format text: APPEAL AGAINST DECISION TO DECLINE REFUSAL Free format text: TRIAL NUMBER: 2007201012848; APPEAL AGAINST DECISION TO DECLINE REFUSAL |
|
J302 | Written judgement (patent court) |
Free format text: JUDGMENT (PATENT COURT) FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20071130 Effective date: 20081002 Free format text: TRIAL NUMBER: 2007201012848; JUDGMENT (PATENT COURT) FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20071130 Effective date: 20081002 |